Adaptimmune Therapeutics PLC ADAPY
0.03
0.01
50.00%
as of 25 Sep
- Market cap
- $14.6M
- P/E
- 0.0×
Follow ADAPY
| Dec '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| — | (1,349.52%) | 1,087.18% | (273.57%) |
+8 more TTM periods Free account |
|
| 0.00% | (75.53%) | (34.11%) | (27.17%) | ||
ROIC |
— | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | (311.98%) | (86.91%) | (46.83%) | |
Average Days of Receivables |
— | 52.23 | 8.90 | 29.49 | |
Free Cash Flow per Share |
— | (0.71) | (0.41) | (0.28) | |
Free Cash Flow |
— | (187.58) | (105.74) | (71.02) | |
Capital Expenditures |
— | (1.64) | (1.99) | (1.90) | |
Piotroski F-Score |
— | 0.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
— | 967.31% | (218.23%) | (32.16%) | |
Accounts Receivable Turnover |
— | 11.18 | 28.10 | 23.42 | |
Accounts Payable Turnover |
— | 1.00 | 1.28 | 0.00 | |
Inventory Turnover |
— | 0.00 | 0.00 | — | |
Average Days of Payables |
— | 404.69 | 264.91 | 0.00 | |
Days of Inventory on Hand |
— | 490.32 | 546.40 | 0.00 | |
Tax Rate |
— | (0.02) | (0.03) | (0.03) | |
Research and Development Expense of Revenue |
— | 134.92% | 58.61% | 62.70% | |
Selling, General and Administrative Expense of Revenue |
— | 107.00% | 39.10% | 37.46% | |
Share Based Compensation of Revenue |
— | 10.38% | 4.73% | 6.14% | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 1.09 | 1.46 | 0.96 | |
Depreciation/Fixed assets |
— | 0.55 | 0.53 | 0.51 | |
Capex/Depreciation |
— | (0.11) | (0.13) | (0.12) | |
Revenue per Share |
— | 0.25 | 0.70 | 0.71 | |
Operating CF per Share |
— | (0.70) | (0.40) | (0.27) | |
Capex per Share |
— | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
— | 0.03 | 0.01 | 0.01 | |
Net Profit Margin |
— | (262.46%) | (39.50%) | (40.37%) |
Columns are period end dates